{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T16:07:55Z","timestamp":1784822875946,"version":"3.55.0"},"reference-count":280,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"United States National Institutes of Health","doi-asserted-by":"publisher","award":["1R15CA280767-01A1"],"award-info":[{"award-number":["1R15CA280767-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Uveal melanomas (UMs) metastasize at a high frequency, and metastatic UMs are associated with very poor clinical outcomes. Consequently, there is considerable interest in the genetics and biochemistry of UM and in how these insights may lead to novel and effective approaches to treating it. This work reviews the biology and pharmacotherapy of UM. It also summarizes signaling by the network comprising ERBB receptor tyrosine kinases and EGF family peptide growth factors, including mechanisms of crosstalk with G protein-coupled receptors. Next, this work discusses signaling changes that appear to drive UM, particularly increased signaling by the CYSLTR2\/G\u03b1q\/G\u03b111 pathway. Finally, this work suggests that some of the signaling events that drive UM may be the consequence of crosstalk between the CYSLTR2\/G\u03b1q\/G\u03b111 pathway and the ERBB\/EGF signaling network. Thus, this work proposes that the ERBB\/EGF signaling network may be a novel therapeutic target for UM.<\/jats:p>","DOI":"10.3390\/biom16081079","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T15:05:42Z","timestamp":1784819142000},"page":"1079","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Does the ERBB\/EGF Signaling Network Serve as a Nexus for Oncogenic Signals in Uveal Melanoma?"],"prefix":"10.3390","volume":"16","author":[{"given":"Niusha","family":"Raeesian","sequence":"first","affiliation":[{"name":"Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, AL 36849, USA"},{"name":"Program in Molecular Biotechnology, Department of Applied Biosciences and Process Engineering, Anhalt University of Applied Sciences, 06366 K\u00f6then, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8823-5802","authenticated-orcid":false,"suffix":"II","given":"David J.","family":"Riese","sequence":"additional","affiliation":[{"name":"Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, AL 36849, USA"},{"name":"Cancer Biology and Immunology Research Program, O\u2019Neal Comprehensive Cancer Center, Heersink College of Medicine, University of Alabama-Birmingham, Birmingham, AL 35233, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/j.ophtha.2011.01.040","article-title":"Uveal melanoma: Trends in incidence, treatment, and survival","volume":"118","author":"Singh","year":"2011","journal-title":"Ophthalmology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/eye.2016.275","article-title":"Uveal melanoma: Relatively rare but deadly cancer","volume":"31","author":"Kaliki","year":"2017","journal-title":"Eye"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Damato, B.E., Dukes, J., Goodall, H., and Carvajal, R.D. (2019). Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma. Cancers, 11.","DOI":"10.3390\/cancers11070971"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Piperno-Neumann, S., Piulats, J.M., Goebeler, M., Galloway, I., Lugowska, I., Becker, J.C., Vihinen, P., Van Calster, J., Hadjistilianou, T., and Proenca, R. (2019). Uveal Melanoma: A European Network to Face the Many Challenges of a Rare Cancer. Cancers, 11.","DOI":"10.3390\/cancers11060817"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Sorrentino, F.S., Culiersi, C., Florido, A., De Nadai, K., Adamo, G.G., Nasini, F., Vivarelli, C., Mura, M., and Parmeggiani, F. (2024). Genetic Features of Uveal Melanoma. Genes, 15.","DOI":"10.3390\/genes15111356"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"778","DOI":"10.3390\/curroncol31020058","article-title":"From Molecular Biology to Novel Immunotherapies and Nanomedicine in Uveal Melanoma","volume":"31","author":"Synoradzki","year":"2024","journal-title":"Curr. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/978-1-62703-727-3_22","article-title":"A prognostic test to predict the risk of metastasis in uveal melanoma based on a 15-gene expression profile","volume":"1102","author":"Harbour","year":"2014","journal-title":"Methods Mol. Biol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"7205","DOI":"10.1158\/0008-5472.CAN-04-1750","article-title":"Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death","volume":"64","author":"Onken","year":"2004","journal-title":"Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0039-6257(88)90173-7","article-title":"Epidemiologic aspects of uveal melanoma","volume":"32","author":"Egan","year":"1988","journal-title":"Surv. Ophthalmol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Fuentes-Rodriguez, A., Mitchell, A., Guerin, S.L., and Landreville, S. (2024). Recent Advances in Molecular and Genetic Research on Uveal Melanoma. Cells, 13.","DOI":"10.3390\/cells13121023"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Singh, S.R.K., Malapati, S.J., Kumar, R., Willner, C., and Wang, D. (2021). NCDB Analysis of Melanoma 2004-2015: Epidemiology and Outcomes by Subtype, Sociodemographic Factors Impacting Clinical Presentation, and Real-World Survival Benefit of Immunotherapy Approval. Cancers, 13.","DOI":"10.3390\/cancers13061455"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41571-022-00714-1","article-title":"Advances in the clinical management of uveal melanoma","volume":"20","author":"Carvajal","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/eye.2011.272","article-title":"Differences in uveal melanomas between men and women from the British Isles","volume":"26","author":"Damato","year":"2012","journal-title":"Eye"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/eye.2012.126","article-title":"Progress in the management of patients with uveal melanoma. The 2012 Ashton Lecture","volume":"26","author":"Damato","year":"2012","journal-title":"Eye"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2147\/OPTH.S89591","article-title":"Uveal melanoma: Epidemiology, etiology, and treatment of primary disease","volume":"11","author":"Krantz","year":"2017","journal-title":"Clin. Ophthalmol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"100060","DOI":"10.1016\/j.apjo.2024.100060","article-title":"Uveal melanoma: Current evidence on prognosis, treatment and potential developments","volume":"13","author":"Gelmi","year":"2024","journal-title":"Asia Pac. J. Ophthalmol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Kulbay, M., Marcotte, E., Remtulla, R., Lau, T.H.A., Paez-Escamilla, M., Wu, K.Y., and Burnier, M.N. (2024). Uveal Melanoma: Comprehensive Review of Its Pathophysiology, Diagnosis, Treatment, and Future Perspectives. Biomedicines, 12.","DOI":"10.3390\/biomedicines12081758"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.preteyeres.2018.03.004","article-title":"Ocular treatment of choroidal melanoma in relation to the prevention of metastatic death\u2014A personal view","volume":"66","author":"Damato","year":"2018","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1755-3768.1982.tb08371.x","article-title":"Malignant melanomas of the human uvea: 25-year follow-up of cases in Denmark, 1943--1952","volume":"60","author":"Jensen","year":"1982","journal-title":"Acta Ophthalmol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1167\/iovs.03-0538","article-title":"Very long-term prognosis of patients with malignant uveal melanoma","volume":"44","author":"Kujala","year":"2003","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1136\/bjophthalmol-2016-309034","article-title":"Metastatic disease from uveal melanoma: Treatment options and future prospects","volume":"101","author":"Carvajal","year":"2017","journal-title":"Br. J. Ophthalmol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1159\/000480640","article-title":"Uveal Melanoma: 5-Year Update on Incidence, Treatment, and Survival (SEER 1973-2013)","volume":"4","author":"Aronow","year":"2018","journal-title":"Ocul. Oncol. Pathol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1093\/annonc\/mdz176","article-title":"Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: An international rare cancers initiative (IRCI) ocular melanoma study","volume":"30","author":"Khoja","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/CMR.0000000000000575","article-title":"Overall survival after treatment for metastatic uveal melanoma: A systematic review and meta-analysis","volume":"29","author":"Rantala","year":"2019","journal-title":"Melanoma Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41572-020-0158-0","article-title":"Uveal melanoma","volume":"6","author":"Jager","year":"2020","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.semcancer.2020.05.003","article-title":"Uveal melanoma pathobiology: Metastasis to the liver","volume":"71","author":"Bustamante","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000509918","article-title":"Five Decades of Enucleations for Uveal Melanoma in One Center: More Tumors with High Risk Factors, No Improvement in Survival over Time","volume":"7","author":"Roelofsen","year":"2021","journal-title":"Ocul. Oncol. Pathol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"pkad097","DOI":"10.1093\/jncics\/pkad097","article-title":"Comprehensive causes of death in uveal melanoma: Mortality in 1530 consecutively diagnosed patients followed until death","volume":"7","author":"Stalhammar","year":"2023","journal-title":"JNCI Cancer Spectr."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/pcmr.13161","article-title":"Emerging therapeutic strategies for metastatic uveal melanoma: Targeting driver mutations","volume":"37","author":"Liu","year":"2024","journal-title":"Pigment. Cell Melanoma Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4254","DOI":"10.1167\/iovs.08-2033","article-title":"Gene expression profiling in uveal melanoma: Two regions on 3p related to prognosis","volume":"49","author":"Lodder","year":"2008","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_31","unstructured":"(2025, July 23). NCCN Guidelines: Melanoma: Uveal, Version 1. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/uveal.pdf."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Houtzagers, L.E., Wierenga, A.P.A., Ruys, A.A.M., Luyten, G.P.M., and Jager, M.J. (2020). Iris Colour and the Risk of Developing Uveal Melanoma. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21197172"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1167\/iovs.64.13.45","article-title":"Worldwide Incidence of Ocular Melanoma and Correlation With Pigmentation-Related Risk Factors","volume":"64","author":"Wu","year":"2023","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.ajhg.2016.09.008","article-title":"Comprehensive Genetic Landscape of Uveal Melanoma by Whole-Genome Sequencing","volume":"99","author":"Torsello","year":"2016","journal-title":"Am. J. Hum. Genet."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nature07586","article-title":"Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi","volume":"457","author":"Bezrookove","year":"2009","journal-title":"Nature"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1056\/NEJMoa1000584","article-title":"Mutations in GNA11 in uveal melanoma","volume":"363","author":"Griewank","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"van der Kooij, M.K., Speetjens, F.M., van der Burg, S.H., and Kapiteijn, E. (2019). Uveal Versus Cutaneous Melanoma; Same Origin, Very Distinct Tumor Types. Cancers, 11.","DOI":"10.3390\/cancers11060845"},{"key":"ref_39","first-page":"29","article-title":"Identifying biomarkers and novel therapeutic targets in uveal melanoma","volume":"22","author":"Wessely","year":"2024","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/ICU.0000000000000761","article-title":"Radiation therapy for uveal melanoma: A review of treatment methods available in 2021","volume":"32","author":"Reichstein","year":"2021","journal-title":"Curr. Opin. Ophthalmol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Collaborative Ocular Melanoma Study Group (2001). Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. Arch. Ophthalmol., 119, 670\u2013676.","DOI":"10.1001\/archopht.119.5.670"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1177\/1120672121995131","article-title":"Conjunctival and uveal melanoma: Survival and risk factors following orbital exenteration","volume":"32","author":"Baum","year":"2022","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"101607","DOI":"10.1016\/j.ajoc.2022.101607","article-title":"Local recurrence of uveal melanoma and concomitant brain metastases associated with an activating telomerase promoter mutation seven years after secondary enucleation","volume":"27","author":"Heng","year":"2022","journal-title":"Am. J. Ophthalmol. Case Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1038\/s41433-021-01710-y","article-title":"Survival analysis following enucleation for uveal melanoma","volume":"36","author":"Negretti","year":"2022","journal-title":"Eye"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s10384-019-00656-9","article-title":"Clinical predictors of survival in metastatic uveal melanoma","volume":"63","author":"Lorenzo","year":"2019","journal-title":"Jpn. J. Ophthalmol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2353\/jmoldx.2010.090220","article-title":"An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma","volume":"12","author":"Onken","year":"2010","journal-title":"J. Mol. Diagn."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1002\/1097-0142(19930401)71:7<2299::AID-CNCR2820710721>3.0.CO;2-G","article-title":"Biologic distinctions between cure and time to death in 2892 patients with intraocular melanoma","volume":"71","author":"Gamel","year":"1993","journal-title":"Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s43856-022-00082-y","article-title":"Long-term relative survival in uveal melanoma: A systematic review and meta-analysis","volume":"2","author":"Stalhammar","year":"2022","journal-title":"Commun. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1002\/ijc.28436","article-title":"Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma","volume":"134","author":"Bidard","year":"2014","journal-title":"Int. J. Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1093\/annonc\/mdx212","article-title":"Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: A proof-of-concept study","volume":"28","author":"Cabel","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Park, J.J., Diefenbach, R.J., Byrne, N., Long, G.V., Scolyer, R.A., Gray, E.S., Carlino, M.S., and Rizos, H. (2021). Circulating Tumor DNA Reflects Uveal Melanoma Responses to Protein Kinase C Inhibition. Cancers, 13.","DOI":"10.3390\/cancers13071740"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ccell.2017.07.003","article-title":"Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma","volume":"32","author":"Robertson","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1126\/science.1194472","article-title":"Frequent mutation of BAP1 in metastasizing uveal melanomas","volume":"330","author":"Harbour","year":"2010","journal-title":"Science"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: Recent progress and potential biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp. Mol. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1002\/cam4.732","article-title":"Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: A systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials","volume":"5","author":"Yun","year":"2016","journal-title":"Cancer Med."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Champion, P.J., Bluestein, J.R., Quinn, A.E., Bell, S.D., Kiley, J.H., Wakefield, M.R., and Fang, Y. (2025). A Consolidated Review of Contemporary Targeted and Immunotherapeutic Options for Melanoma. Biomedicines, 13.","DOI":"10.3390\/biomedicines13061388"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Timis, T., Buruiana, S., Dima, D., Nistor, M., Muresan, X.M., Cenariu, D., Tigu, A.B., and Tomuleasa, C. (2025). Advances in Cell and Immune Therapies for Melanoma. Biomedicines, 13.","DOI":"10.3390\/biomedicines13010098"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Wang, X., Ma, S., Zhu, S., Zhu, L., and Guo, W. (2025). Advances in Immunotherapy and Targeted Therapy of Malignant Melanoma. Biomedicines, 13.","DOI":"10.3390\/biomedicines13010225"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Saleem, M., Watson, A.E., Anwaar, A., Jasser, A.O., and Yusuf, N. (2025). Optimizing Immunotherapy: The Synergy of Immune Checkpoint Inhibitors with Artificial Intelligence in Melanoma Treatment. Biomolecules, 15.","DOI":"10.3390\/biom15040589"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Triggiano, G., Pezzicoli, G., and Tucci, M. (2025). Immunotherapy in Advanced Cutaneous Melanoma: From the Optimal Treatment Duration to the Impact on Survival in Case of Early Discontinuation Due to Immune-Related Adverse Events. Biomolecules, 15.","DOI":"10.3390\/biom15050651"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/cas.16398","article-title":"PD-1 blockade treatment in melanoma: Mechanism of response and tumor-intrinsic resistance","volume":"116","author":"Wang","year":"2025","journal-title":"Cancer Sci."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Lens, M., and Schachter, J. (2025). Immune Checkpoint Inhibitors in the Treatment of Advanced Melanoma in Older Patients: An Overview of Published Data. Cancers, 17.","DOI":"10.3390\/cancers17111835"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Muto, Y., Fujimura, T., and Asano, Y. (2025). Recent Advances in Immunotherapy for Melanoma: Perspectives on the Development of Novel Treatments: A Mini Review. Cancers, 17.","DOI":"10.3390\/cancers17132265"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.det.2025.03.004","article-title":"Systemic Therapies for Metastatic Melanoma","volume":"43","author":"Latoni","year":"2025","journal-title":"Dermatol. Clin."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"115121","DOI":"10.1016\/j.ejca.2024.115121","article-title":"An updated review of immune checkpoint inhibitors in cutaneous oncology: Beyond melanoma","volume":"214","author":"Pham","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1080\/14712598.2025.2485315","article-title":"Management of metastatic melanoma with combinations including PD-1 inhibitors","volume":"25","author":"Maul","year":"2025","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1080\/14737140.2025.2522944","article-title":"An evaluation of nivolumab and ipilimumab for the treatment of resectable stage III melanoma","volume":"25","author":"McCombe","year":"2025","journal-title":"Expert Rev. Anticancer. Ther."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1200\/JCO-24-01802","article-title":"Combination Immunotherapy With Nivolumab Plus Ipilimumab in Melanoma of Unknown Primary","volume":"43","author":"Patel","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41572-025-00603-8","article-title":"Cutaneous melanoma","volume":"11","author":"Tasdogan","year":"2025","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_70","unstructured":"Pathak, S., and Puckett, Y. (2025). Cutaneous Malignant Melanoma: Guideline-Based Management and Interprofessional Collaboration. StatPearls, StatPearls Publishing."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1177\/12034754241303057","article-title":"Molecular-Guided Therapy for Melanoma in Canada: Overview of Current Practices and Recommendations","volume":"29","author":"Shah","year":"2025","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"290","DOI":"10.6004\/jnccn.2024.0036","article-title":"NCCN Guidelines\u00ae Insights: Melanoma: Cutaneous, Version 2.2024","volume":"22","author":"Swetter","year":"2024","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Wessely, A., Steeb, T., Erdmann, M., Heinzerling, L., Vera, J., Schlaak, M., Berking, C., and Heppt, M.V. (2020). The Role of Immune Checkpoint Blockade in Uveal Melanoma. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21030879"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/IIO.0000000000000263","article-title":"Immune Checkpoint Inhibitors in Uveal and Conjunctival Melanoma","volume":"59","author":"Wierenga","year":"2019","journal-title":"Int. Ophthalmol. Clin."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/0284186X.2016.1260773","article-title":"Anti-PD1 treatment in metastatic uveal melanoma in the Netherlands","volume":"56","author":"Joosse","year":"2017","journal-title":"Acta Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s00251-019-01108-x","article-title":"Prolonged stable disease in a uveal melanoma patient with germline MBD4 nonsense mutation treated with pembrolizumab and ipilimumab","volume":"71","author":"Johansson","year":"2019","journal-title":"Immunogenetics"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1038\/s41467-018-04322-5","article-title":"Outlier response to anti-PD1 in uveal melanoma reveals germline MBD4 mutations in hypermutated tumors","volume":"9","author":"Rodrigues","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.2174\/0929867326666190704141444","article-title":"Immunotherapy for Uveal Melanoma\u2014Current Knowledge and Perspectives","volume":"27","author":"Kastelan","year":"2020","journal-title":"Curr. Med. Chem."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1038\/s41467-020-16276-8","article-title":"Whole genome landscapes of uveal melanoma show an ultraviolet radiation signature in iris tumours","volume":"11","author":"Johansson","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor Mutational Burden and Response Rate to PD-1 Inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"114","DOI":"10.6004\/jnccn.2018.7070","article-title":"Response to Anti-PD-1 in Uveal Melanoma Without High-Volume Liver Metastasis","volume":"17","author":"Johnson","year":"2019","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1002\/cncr.30258","article-title":"Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies","volume":"122","author":"Algazi","year":"2016","journal-title":"Cancer"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2147\/TACG.S69210","article-title":"The genetics of uveal melanoma: Current insights","volume":"9","author":"Helgadottir","year":"2016","journal-title":"Appl. Clin. Genet."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S1470-2045(17)30251-6","article-title":"Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: A single-centre, two-stage, single-arm, phase 2 study","volume":"18","author":"Chandran","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Retel, V.P., Steuten, L.M.G., Geukes Foppen, M.H., Mewes, J.C., Lindenberg, M.A., Haanen, J., and van Harten, W.H. (2018). Early cost-effectiveness of tumor infiltrating lymphocytes (TIL) for second line treatment in advanced melanoma: A model-based economic evaluation. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4788-5"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","article-title":"Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy","volume":"17","author":"Rosenberg","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1158\/1078-0432.CCR-15-1879","article-title":"Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen","volume":"22","author":"Andersen","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Martinez-Perez, D., Vinal, D., Solares, I., Espinosa, E., and Feliu, J. (2021). Gp-100 as a Novel Therapeutic Target in Uveal Melanoma. Cancers, 13.","DOI":"10.3390\/cancers13235968"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s002620050379","article-title":"Analysis of Pmel17\/gp100 expression in primary human tissue specimens: Implications for melanoma immuno- and gene-therapy","volume":"44","author":"Wagner","year":"1997","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.4049\/jimmunol.154.8.3961","article-title":"Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression","volume":"154","author":"Kawakami","year":"1995","journal-title":"J. Immunol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/ijc.2910620118","article-title":"Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by an HLA-A2.1-restricted anti-melanoma CTL line","volume":"62","author":"Bakker","year":"1995","journal-title":"Int. J. Cancer"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1056\/NEJMoa1012863","article-title":"gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma","volume":"364","author":"Schwartzentruber","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_94","unstructured":"(2025, August 10). Safety and Efficacy of IMCgp100 Versus Investigator Choice in Uveal Melanoma, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03070392."},{"key":"ref_95","unstructured":"(2025, August 11). FDA Approves Tebentafusp-Tebn for Unresectable or Metastatic Uveal Melanoma, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2022\/761228Orig1s000ltr.pdf."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1056\/NEJMoa2304753","article-title":"Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma","volume":"389","author":"Hassel","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.annonc.2023.11.013","article-title":"Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: A propensity score-weighted analysis","volume":"35","author":"Piulats","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1167\/iovs.11-8901","article-title":"A comparison of HLA genotype with inflammation in uveal melanoma","volume":"53","author":"Bronkhorst","year":"2012","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_99","first-page":"1175","article-title":"Design and synthesis of BAP-1 inhibitors","volume":"39","author":"Zhang","year":"2026","journal-title":"Pak. J. Pharm. Sci."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1016\/j.apsb.2022.04.016","article-title":"Discovery of small molecule Galphaq\/11 protein inhibitors against uveal melanoma","volume":"12","author":"Ge","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"10156","DOI":"10.1038\/ncomms10156","article-title":"The experimental power of FR900359 to study Gq-regulated biological processes","volume":"6","author":"Schrage","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/nchem.2577","article-title":"Total synthesis and structure-activity relationship studies of a series of selective G protein inhibitors","volume":"8","author":"Xiong","year":"2016","journal-title":"Nat. Chem."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"5206","DOI":"10.1074\/jbc.REV119.007061","article-title":"Heterotrimeric Gq proteins as therapeutic targets?","volume":"295","author":"Kostenis","year":"2020","journal-title":"J. Biol. Chem."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1021\/acs.jmedchem.0c01977","article-title":"Design, Synthesis, and Evaluation of Small Molecule Galphaq\/11 Protein Inhibitors for the Treatment of Uveal Melanoma","volume":"64","author":"Ge","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.chembiol.2014.06.003","article-title":"A cell-permeable inhibitor to trap Galphaq proteins in the empty pocket conformation","volume":"21","author":"Schmitz","year":"2014","journal-title":"Chem. Biol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"100403","DOI":"10.1016\/j.jbc.2021.100403","article-title":"Targeting primary and metastatic uveal melanoma with a G protein inhibitor","volume":"296","author":"Onken","year":"2021","journal-title":"J. Biol. Chem."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Carlino, M.S., Kapiteijn, E., Piperno-Neumann, S., Sullivan, R.J., Carvajal, R., Dummer, R., Gromke, T., Hassel, J.C., Kee, D., and Ramelyte, E. (2026). An anti-PMEL antibody-drug conjugate with a Gq\/11 inhibitor payload in GNAQ\/GNA11-mutant melanomas: A phase 1 trial. Nat. Med.","DOI":"10.1038\/s41591-026-04518-z"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"IA022","DOI":"10.1158\/1538-8514.CANCERCHEM24-IA022","article-title":"Abstract IA022: DYP688, a first-in-class PMEL17-targeted antibody drug conjugate delivering a Gq\/11-specific inhibitor for the treatment of metastatic uveal melanoma","volume":"23","author":"Wk","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V","article-title":"Specificity within the EGF family\/ErbB receptor family signaling network","volume":"20","author":"Riese","year":"1998","journal-title":"Bioessays"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0960-0760(01)00190-X","article-title":"Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: A novel signaling pathway with potential significance for breast cancer","volume":"80","author":"Filardo","year":"2002","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.yexcr.2008.10.011","article-title":"The role of protease activity in ErbB biology","volume":"315","author":"Blobel","year":"2009","journal-title":"Exp. Cell Res."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ccr.2014.02.025","article-title":"ERBB receptors: From oncogene discovery to basic science to mechanism-based cancer therapeutics","volume":"25","author":"Arteaga","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"110092","DOI":"10.1016\/j.cellsig.2021.110092","article-title":"GPCR-ErbB transactivation pathways and clinical implications","volume":"86","author":"Palanisamy","year":"2021","journal-title":"Cell Signal."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1124\/pharmrev.121.000381","article-title":"The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein","volume":"74","author":"Lucas","year":"2022","journal-title":"Pharmacol. Rev."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1042\/bst0311203","article-title":"EGFR signal transactivation in cancer cells","volume":"31","author":"Fischer","year":"2003","journal-title":"Biochem. Soc. Trans."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.bbapap.2004.11.009","article-title":"ADAM-mediated ectodomain shedding of HB-EGF in receptor cross-talk","volume":"1751","author":"Higashiyama","year":"2005","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_117","first-page":"31","article-title":"EGFR may couple moderate alcohol consumption to increased breast cancer risk","volume":"1","author":"Mill","year":"2009","journal-title":"Breast Cancer"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"C1\u201310","DOI":"10.1152\/ajpcell.00620.2005","article-title":"ADAMs as mediators of EGF receptor transactivation by G protein-coupled receptors","volume":"291","author":"Ohtsu","year":"2006","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2008.11.008","article-title":"Functional selectivity of EGF family peptide growth factors: Implications for cancer","volume":"122","author":"Wilson","year":"2009","journal-title":"Pharmacol. Ther."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"5258","DOI":"10.1111\/febs.12509","article-title":"Unravelling the molecular complexity of GPCR-mediated EGFR transactivation using functional genomics approaches","volume":"280","author":"George","year":"2013","journal-title":"FEBS J."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1016\/j.bmcl.2017.07.002","article-title":"GPCRs and EGFR\u2014Cross-talk of membrane receptors in cancer","volume":"27","author":"Kose","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12929-025-01119-9","article-title":"EGF receptor in organ development, tissue homeostasis and regeneration","volume":"32","author":"Tito","year":"2025","journal-title":"J. Biomed. Sci."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"e2400992","DOI":"10.1002\/ardp.202400992","article-title":"A Structural Insight Into Two Important ErbB Receptors (EGFR and HER2) and Their Relevance to Non-Small Cell Lung Cancer","volume":"358","author":"Topalan","year":"2025","journal-title":"Arch. Pharm."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s13402-020-00499-4","article-title":"The role of ErbB4 in cancer","volume":"43","author":"Segers","year":"2020","journal-title":"Cell. Oncol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-4939-7219-7_1","article-title":"ErbB Receptors and Cancer","volume":"1652","author":"Wang","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10911-008-9083-7","article-title":"ERBB3\/HER3 and ERBB2\/HER2 duet in mammary development and breast cancer","volume":"13","author":"Stern","year":"2008","journal-title":"J. Mammary Gland Biol. Neoplasia"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1080\/14728222.2025.2532390","article-title":"NRG\/ErbB signaling: On the trail of a molecular fingerprint in mucinous carcinoma","volume":"29","author":"Trombetta","year":"2025","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41571-025-01085-z","article-title":"Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC\u2014Mechanisms and evolving treatment approaches","volume":"23","author":"Zhao","year":"2026","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"114747","DOI":"10.1016\/j.jconrel.2026.114747","article-title":"The emerging role of antibody-drug conjugates in EGFR-mutant non-small cell lung cancer with acquired resistance to third-generation EGFR tyrosine kinase inhibitors","volume":"393","author":"Zhang","year":"2026","journal-title":"J. Control. Release"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"4737","DOI":"10.1007\/s00210-025-04596-9","article-title":"EGFR-targeted tyrosine kinase inhibitors: Advancements in cancer therapy","volume":"399","author":"Ali","year":"2026","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Ding, C., Yao, R., Wang, Y., Liu, H., Li, C., and Xie, H. (2025). An overview of mechanisms, biomarkers, and treatment strategies for acquired anti-EGFR resistance in RAS wild-type colorectal cancer. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1656372"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"30905","DOI":"10.34172\/bi.30905","article-title":"Potential role of epidermal growth factor receptors (EGFR) signaling in the pathogenesis and management of hepatocellular carcinoma","volume":"15","author":"Patil","year":"2025","journal-title":"Bioimpacts"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"108066","DOI":"10.1016\/j.phrs.2025.108066","article-title":"Antibody-drug conjugates: A new twist to overcome EGFR-TKIs resistance in non-small cell lung cancer","volume":"223","author":"Deng","year":"2026","journal-title":"Pharmacol. Res."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/1878-0261.13754","article-title":"When molecular biology transforms clinical oncology: The EGFR journey in colorectal cancer","volume":"19","author":"Vitiello","year":"2025","journal-title":"Mol. Oncol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s12032-025-02652-1","article-title":"Targeting EGFR and PI3K\/mTOR pathways in glioblastoma: Innovative therapeutic approaches","volume":"42","author":"Singh","year":"2025","journal-title":"Med. Oncol."},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Joshi, H., and Sheikh, M.S. (2025). Cell Death, Molecular Targeted Therapies, and Metabolic Reprogramming in EGFR-Mutant Lung Cancer. Cancers, 17.","DOI":"10.3390\/cancers17172791"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"100076","DOI":"10.1016\/j.pharmr.2025.100076","article-title":"Cracking the EGFR code: Cancer biology, resistance mechanisms, and future therapeutic frontiers","volume":"77","author":"Du","year":"2025","journal-title":"Pharmacol. Rev."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"520","DOI":"10.2174\/1389450116666150107153609","article-title":"EGFR Transactivation by Peptide G Protein-Coupled Receptors in Cancer","volume":"17","author":"Moody","year":"2016","journal-title":"Curr. Drug Targets"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3109\/08977194.2011.649918","article-title":"EGFR ligands exhibit functional differences in models of paracrine and autocrine signaling","volume":"30","author":"Wilson","year":"2012","journal-title":"Growth Factors"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nrm1962","article-title":"EGF-ERBB signalling: Towards the systems level","volume":"7","author":"Citri","year":"2006","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s10637-018-0684-8","article-title":"Advanced development of ErbB family-targeted therapies in osteosarcoma treatment","volume":"37","author":"Wang","year":"2019","journal-title":"Investig. New Drugs"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1080\/21541248.2016.1221273","article-title":"The P-Rex1\/Rac signaling pathway as a point of convergence for HER\/ErbB receptor and GPCR responses","volume":"9","author":"Kazanietz","year":"2018","journal-title":"Small GTPases"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"5815","DOI":"10.1158\/1078-0432.CCR-18-1397","article-title":"Rates of ERBB2 Alterations across Melanoma Subtypes and a Complete Response to Trastuzumab Emtansine in an ERBB2-Amplified Acral Melanoma","volume":"24","author":"Gottesdiener","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11033-025-11202-x","article-title":"HER2 as a molecular trojan horse in prostate cancer: Mechanistic insights and therapeutic unlocks","volume":"53","author":"Mukherjee","year":"2025","journal-title":"Mol. Biol. Rep."},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Arienti, C., Pignatta, S., and Tesei, A. (2019). Epidermal Growth Factor Receptor Family and its Role in Gastric Cancer. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.01308"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1097\/CM9.0000000000004016","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitor for the treatment of non-small cell lung cancer in the past 30 years (1997\u20132026)","volume":"139","author":"Xie","year":"2026","journal-title":"Chin. Med. J."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"105207","DOI":"10.1016\/j.critrevonc.2026.105207","article-title":"Beyond EGFR inhibition in head and neck squamous cell carcinoma: Overcoming resistance mechanisms and novel therapeutic frontiers","volume":"221","author":"Carosi","year":"2026","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"105327","DOI":"10.1016\/j.critrevonc.2026.105327","article-title":"Epidermal growth factor receptor (EGFR) atypical mutations in non-small-cell lung cancer (NSCLC): \u2018Where the streets have no name\u2019","volume":"223","author":"Spitaleri","year":"2026","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"118538","DOI":"10.1016\/j.ejmech.2025.118538","article-title":"Medicinal chemistry perspective on quinazoline derivatives: Sustainable synthetic routes, anticancer evaluation, and SAR analysis","volume":"304","author":"Dutta","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"11","DOI":"10.15430\/JCP.25.052","article-title":"From Gefitinib to Amivantamab: Progress and Perspectives of Therapies Targeting the Epidermal Growth Factor Receptor in the Era of Precision Oncology","volume":"31","author":"Liu","year":"2026","journal-title":"J. Cancer Prev."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"144","DOI":"10.21037\/tlcr-2026-1-0061","article-title":"Lung cancer with EGFR PACC mutations: A practical review of available treatment options and novel therapies on the horizon","volume":"15","author":"Berg","year":"2026","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"3893","DOI":"10.1039\/D4MD00799A","article-title":"A momentous progress update: Epidermal growth factor receptor inhibitors as viable agents for combating cancer","volume":"16","author":"Jangra","year":"2025","journal-title":"RSC Med. Chem."},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Wang, C., Xiao, D., and Zhai, C. (2025). Efficacy and safety of small-molecule TKIs in neoadjuvant treatment of HER2-positive breast cancer: A systematic review and network meta-analysis. BMC Cancer, 25.","DOI":"10.1186\/s12885-025-14404-5"},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Suryawanshi, M.V., Girase, R.T., Bagul, V.S., and Gujarathi, P.P. (2026). Exploring tyrosine kinase inhibitors for HER2-positive breast cancer: Comprehensive review on a complete pharmacology-molecular mechanisms, safety profiles, and insights from preclinical and clinical studies. Clin. Transl. Oncol.","DOI":"10.1007\/s12094-026-04331-7"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1080\/17568919.2025.2498881","article-title":"The antibreast cancer therapeutic potential of quinazoline hybrids-Part I","volume":"17","author":"Chen","year":"2025","journal-title":"Future Med. Chem."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1080\/17568919.2025.2515816","article-title":"The current status of quinazoline hybrids with antibreast cancer therapeutic potential-part II","volume":"17","author":"Zeng","year":"2025","journal-title":"Future Med. Chem."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11060-026-05599-z","article-title":"A review of targeted therapies for NF2-related vestibular schwannoma: Molecular pathogenesis, emerging therapeutics, and future clinical horizons","volume":"178","author":"Sokol","year":"2026","journal-title":"J. Neuro-Oncol."},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Maione, P., Romano, F.J., and Gridelli, C. (2026). Amivantamab Plus Lazertinib and Platin-Based Chemotherapy Plus Osimertinib in EGFR-Mutant NSCLC: How to Choose Among Them and When Is Monotherapy with Osimertinib Still the Best Option?. Curr. Oncol., 33.","DOI":"10.3390\/curroncol33010054"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40265-025-02276-9","article-title":"First Line and Treatment Sequencing in EGFR-Mutated Metastatic NSCLC: What is Right for Which Patient?","volume":"86","author":"Abdayem","year":"2026","journal-title":"Drugs"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"101717","DOI":"10.1016\/j.gendis.2025.101717","article-title":"A comprehensive proteomic analysis uncovers novel molecular subtypes of gastric signet ring cell carcinoma: Identification of potential prognostic biomarkers and therapeutic targets","volume":"13","author":"Jin","year":"2026","journal-title":"Genes. Dis."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"103138","DOI":"10.1016\/j.ctrv.2026.103138","article-title":"Perioperative strategies for resectable EGFR-Mutant NSCLC: Evidence hierarchy and clinical decision-making","volume":"146","author":"Zhao","year":"2026","journal-title":"Cancer Treat. Rev."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1002\/ijc.70318","article-title":"Cutting edge therapies: A review of Food and Drug Administration-approved drugs for non-small cell lung cancer","volume":"158","author":"Mayuri","year":"2026","journal-title":"Int. J. Cancer"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s40265-026-02299-w","article-title":"Sevabertinib: First Approval","volume":"86","author":"Keam","year":"2026","journal-title":"Drugs"},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Richani Meinhardt, F.W., Zambrano Iglesias, M.I., Fernandez Gomez, M.P., Saltaren Fonseca, J.F., Hussein, A., and Raez, L.E. (2026). HER2 Therapies in Non-Small Cell Lung Cancer (NSCLC). Int. J. Mol. Sci., 27.","DOI":"10.3390\/ijms27114910"},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Balli, S., Basoglu, T., and Ozdogan, M. (2026). Evolving treatment strategies for HER2-altered non-small-cell lung cancer: The rise of TKIs and ADCs. Front. Oncol., 16.","DOI":"10.3389\/fonc.2026.1771869"},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"Muscolino, P., Fassi, E., Signorelli, D., Colonese, F., Cortinovis, D.L., Lo Russo, G., Pasello, G., Infurna, C., Ciappina, G., and Berretta, M. (2026). HER2 Alterations in Non-Small Cell Lung Cancer: Emerging Perspectives on the Therapeutic Landscape. Int. J. Mol. Sci., 27.","DOI":"10.3390\/ijms27052334"},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Del Rio, B., Masini, S., Caceres-Galvis, C., Torres-Jimenez, J., Bote, H., Zurera, M., Baena, J., Serrano, C., Nunez, J.A., and Ponce-Aix, S. (2026). Emerging Targeted Therapies for HER2-Mutant NSCLC. J. Thorac. Oncol., 103899.","DOI":"10.1016\/j.jtho.2026.103899"},{"key":"ref_169","doi-asserted-by":"crossref","unstructured":"Chang, L., Wang, M., Zhang, H., Li, Z., Song, Z., Zhao, L., Jiang, F., Wang, J., and Quan, Y. (2026). Synthesis and Clinical Application of Small-Molecule Drugs Approved by FDA in 2025. Med. Res. Rev.","DOI":"10.1002\/med.70064"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s11523-026-01213-4","article-title":"Epidemiology and Real-World Outcomes in Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Mutant Non-small Cell Lung Cancer by Region: A Targeted Literature Review","volume":"21","author":"Goto","year":"2026","journal-title":"Target. Oncol."},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Rosas, D., Desai, J., and Raez, L. (2026). Therapeutic Advances in Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations: From Molecular Biology to Targeted Therapy. Int. J. Mol. Sci., 27.","DOI":"10.3390\/ijms27093714"},{"key":"ref_172","doi-asserted-by":"crossref","unstructured":"Zhou, C., Greillier, L., Liu, G., John, T., Xing, L., Kowalski, D., Memmott, R.M., Yazici, O., Sun, M., and Shu, C. (2026). First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations. N. Engl. J. Med.","DOI":"10.1056\/NEJMoa2604461"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"108107","DOI":"10.1016\/j.phrs.2026.108107","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: A 2026 update","volume":"224","author":"Roskoski","year":"2026","journal-title":"Pharmacol. Res."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1080\/13543784.2025.2472411","article-title":"Tucatinib in the treatment of HER2-overexpressing gastrointestinal cancers: Current insights and future prospects","volume":"34","author":"Hoyek","year":"2025","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.clbc.2025.06.004","article-title":"Sequential Therapy With HER2 Tyrosine Kinase Inhibitors in Patients With HER2-Positive Metastatic Breast Cancer","volume":"25","author":"Shagisultanova","year":"2025","journal-title":"Clin. Breast Cancer"},{"key":"ref_176","doi-asserted-by":"crossref","unstructured":"De, A., Dey, P., Bishnu, A., Patel, J., Mishra, S., Gadewal, N., Ray, P., and Gupta, S. (2025). Hotspot mutations in HER2 interfaces destabilize structure, causing breast cancer treatment failure. Res. Sq.","DOI":"10.21203\/rs.3.rs-5931887\/v1"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1080\/14796694.2026.2658641","article-title":"Evaluating zongertinib in the treatment of patients with HER2-mutant non-small cell lung cancer","volume":"22","author":"Kim","year":"2026","journal-title":"Future Oncol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1016\/j.ejca.2013.06.011","article-title":"Evidence of epidermal growth factor receptor expression in uveal melanoma: Inhibition of epidermal growth factor-mediated signalling by Gefitinib and Cetuximab triggered antibody-dependent cellular cytotoxicity","volume":"49","author":"Amaro","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1600-0560.2011.01673.x","article-title":"EGFR in melanoma: Clinical significance and potential therapeutic target","volume":"38","author":"Boone","year":"2011","journal-title":"J. Cutan. Pathol."},{"key":"ref_180","doi-asserted-by":"crossref","unstructured":"Abbas, N., Mourad, M., Smaily, H., Al Mahmasani, L., and Shamseddine, A. (2026). EGFR Signaling in Colorectal Cancer: Novel Therapeutic Strategies, Predictive Biomarkers, and Counteracting Treatment Resistance. Int. J. Mol. Sci., 27.","DOI":"10.3390\/ijms27073265"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"120082","DOI":"10.1016\/j.ijpharm.2020.120082","article-title":"EGFR targeting for cancer therapy: Pharmacology and immunoconjugates with drugs and nanoparticles","volume":"592","author":"Santos","year":"2021","journal-title":"Int. J. Pharm."},{"key":"ref_182","doi-asserted-by":"crossref","unstructured":"Cai, W.Q., Zeng, L.S., Wang, L.F., Wang, Y.Y., Cheng, J.T., Zhang, Y., Han, Z.W., Zhou, Y., Huang, S.L., and Wang, X.W. (2020). The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.01249"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2217\/fon-2018-0594","article-title":"Necitumumab for the treatment of advanced non-small-cell lung cancer","volume":"15","year":"2019","journal-title":"Future Oncol."},{"key":"ref_184","doi-asserted-by":"crossref","unstructured":"Allu, S., Saravanan, Y., Sakthivel, K.M., Chinnadurai, K., Kumar, P., Saravanan, M., and Rasmi, R.R. (2026). Decoding the Genetic Hallmarks of Breast Cancer: Molecular Signatures, Prognostic and Therapeutic Perspectives. Appl. Biochem. Biotechnol.","DOI":"10.1007\/s12010-026-05720-y"},{"key":"ref_185","doi-asserted-by":"crossref","unstructured":"Esen, S.A., Uncu, D., and Sendur, M.A.N. (2026). Long-term cardiotoxicity outcomes of trastuzumab and cardiac safety of novel HER2-targeted therapies. Expert Opin. Drug Saf., 1\u201310.","DOI":"10.1080\/14740338.2026.2667402"},{"key":"ref_186","doi-asserted-by":"crossref","unstructured":"Kawczak, P., and Baczek, T. (2026). Molecular Targeting of EGFR, BRAF, and HER2 Signaling in Colorectal Cancer: Contemporary Advances with Panitumumab, Encorafenib, and Tucatinib. J. Clin. Med., 15.","DOI":"10.3390\/jcm15062387"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s12672-025-02239-2","article-title":"T-DM1 with concurrent radiotherapy in HER2-positive breast cancer: Preclinical evaluation and mechanisms, prediction, and exploration of adverse effects","volume":"16","author":"Wan","year":"2025","journal-title":"Discov. Oncol."},{"key":"ref_188","unstructured":"Riese, D.J. (2026, July 19). EGF Binding and EGFR Dimerization. Available online: https:\/\/BioRender.com\/gcswiuw."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3892\/ol.2025.15335","article-title":"Role of signaling pathways in lung cancer development and advances in targeted therapies (Review)","volume":"30","author":"Tao","year":"2025","journal-title":"Oncol. Lett."},{"key":"ref_190","unstructured":"Riese, D.J. (2026, July 19). ERBB Receptor Trans-Phosphorylation. Available online: https:\/\/BioRender.com\/xj19yq8."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1517\/17460441.2011.547468","article-title":"Ligand-based receptor tyrosine kinase partial agonists: New paradigm for cancer drug discovery?","volume":"6","author":"Riese","year":"2011","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/sj.onc.1200873","article-title":"Dimerization of the p185neu transmembrane domain is necessary but not sufficient for transformation","volume":"14","author":"Burke","year":"1997","journal-title":"Oncogene"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"5371","DOI":"10.1128\/MCB.18.9.5371","article-title":"Activation of Neu (ErbB-2) mediated by disulfide bond-induced dimerization reveals a receptor tyrosine kinase dimer interface","volume":"18","author":"Burke","year":"1998","journal-title":"Mol. Cell. Biol."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.bbrc.2007.10.004","article-title":"Inter-conversion of neuregulin2 full and partial agonists for ErbB4","volume":"364","author":"Wilson","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1042\/BJ20110921","article-title":"The Q43L mutant of neuregulin 2beta is a pan-ErbB receptor antagonist","volume":"443","author":"Wilson","year":"2012","journal-title":"Biochem. J."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/s41586-021-04393-3","article-title":"Glioblastoma mutations alter EGFR dimer structure to prevent ligand bias","volume":"602","author":"Hu","year":"2022","journal-title":"Nature"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"143212","DOI":"10.1016\/j.ijbiomac.2025.143212","article-title":"Transforming growth factor alpha: Key insights into physiological role, cancer therapeutics, and biomarker potential (A review)","volume":"310","author":"Gaba","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.cell.2017.09.017","article-title":"EGFR Ligands Differentially Stabilize Receptor Dimers to Specify Signaling Kinetics","volume":"171","author":"Freed","year":"2017","journal-title":"Cell"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"101354","DOI":"10.1016\/j.gendis.2024.101354","article-title":"HER3: Unmasking a twist in the tale of a previously unsuccessful therapeutic pursuit targeting a key cancer survival pathway","volume":"12","author":"Desai","year":"2025","journal-title":"Genes. Dis."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1080\/14728222.2025.2540355","article-title":"HER3 in breast cancer: Molecular insights, clinical implications, and therapeutic horizons","volume":"29","author":"Ergun","year":"2025","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/s41571-025-01008-y","article-title":"Emerging importance of HER3 in tumorigenesis and cancer therapy","volume":"22","author":"Garrett","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3727\/000000006783981134","article-title":"Phosphorylation of ErbB4 on tyrosine 1056 is critical for ErbB4 coupling to inhibition of colony formation by human mammary cell lines","volume":"16","author":"Pitfield","year":"2006","journal-title":"Oncol. Res."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.yexcr.2010.11.007","article-title":"Ligand stimulation of ErbB4 and a constitutively-active ErbB4 mutant result in different biological responses in human pancreatic tumor cell lines","volume":"317","author":"Mill","year":"2011","journal-title":"Exp. Cell Res."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1177\/1947601911431080","article-title":"ErbB2 Is Necessary for ErbB4 Ligands to Stimulate Oncogenic Activities in Models of Human Breast Cancer","volume":"2","author":"Mill","year":"2011","journal-title":"Genes Cancer"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1158\/1541-7786.MCR-09-0131","article-title":"Reconstitution of amphiregulin-epidermal growth factor receptor signaling in lung squamous cell carcinomas activates PTHrP gene expression and contributes to cancer-mediated diseases of the bone","volume":"7","author":"Gilmore","year":"2009","journal-title":"Mol. Cancer Res."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s10549-007-9748-8","article-title":"Amphiregulin-EGFR signaling regulates PTHrP gene expression in breast cancer cells","volume":"110","author":"Gilmore","year":"2008","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"34737","DOI":"10.1074\/jbc.M003756200","article-title":"Heregulin-dependent trafficking and cleavage of ErbB-4","volume":"275","author":"Zhou","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1126\/science.1065412","article-title":"gamma -Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase","volume":"294","author":"Ni","year":"2001","journal-title":"Science"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S0014-4827(02)00100-3","article-title":"ErbB-4: Mechanism of action and biology","volume":"284","author":"Carpenter","year":"2003","journal-title":"Exp. Cell Res."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0955-0674(03)00015-2","article-title":"Nuclear localization and possible functions of receptor tyrosine kinases","volume":"15","author":"Carpenter","year":"2003","journal-title":"Curr. Opin. Cell Biol."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.cell.2006.09.013","article-title":"Nuclear signaling by receptor tyrosine kinases: The first robin of spring","volume":"127","author":"Schlessinger","year":"2006","journal-title":"Cell"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3727\/0965040042707907","article-title":"secErbB4-26\/549 antagonizes ligand-induced ErbB4 tyrosine phosphorylation","volume":"14","author":"Gilmore","year":"2004","journal-title":"Oncol. Res."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"6318","DOI":"10.1074\/jbc.M110371200","article-title":"Presenilin-dependent gamma-secretase-like intramembrane cleavage of ErbB4","volume":"277","author":"Lee","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"25373","DOI":"10.1074\/jbc.M603998200","article-title":"ErbB-4 s80 intracellular domain abrogates ETO2-dependent transcriptional repression","volume":"281","author":"Linggi","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"6412","DOI":"10.1158\/0008-5472.CAN-05-2368","article-title":"The ERBB4\/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells","volume":"66","author":"Naresh","year":"2006","journal-title":"Cancer Res."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S1535-6108(02)00127-7","article-title":"Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics","volume":"2","author":"Letai","year":"2002","journal-title":"Cancer Cell"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1083\/jcb.200403155","article-title":"The ERBB4\/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperone","volume":"167","author":"Williams","year":"2004","journal-title":"J. Cell Biol."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/42750","article-title":"A signature motif in transcriptional co-activators mediates binding to nuclear receptors","volume":"387","author":"Heery","year":"1997","journal-title":"Nature"},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.4161\/cc.10.16.17194","article-title":"Function of ERBB4 is determined by alternative splicing","volume":"10","author":"Veikkolainen","year":"2011","journal-title":"Cell Cycle"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s11302-022-09913-y","article-title":"Transactivation of receptor tyrosine kinases by purinergic P2Y and adenosine receptors","volume":"19","author":"Coddou","year":"2023","journal-title":"Purinergic Signal."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.tips.2018.01.001","article-title":"New Insights into Modes of GPCR Activation","volume":"39","author":"Wang","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.coemr.2020.10.003","article-title":"Transactivation of G protein-coupled receptors (GPCRs) and receptor tyrosine kinases (RTKs): Recent insights using luminescence and fluorescence technologies","volume":"16","author":"Kilpatrick","year":"2021","journal-title":"Curr. Opin. Endocr. Metab. Res."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1750-2187-2-2","article-title":"Molecular mechanisms mediating the G protein-coupled receptor regulation of cell cycle progression","volume":"2","author":"New","year":"2007","journal-title":"J. Mol. Signal."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.redox.2015.12.002","article-title":"Redox-dependent regulation of epidermal growth factor receptor signaling","volume":"8","author":"Heppner","year":"2016","journal-title":"Redox Biol."},{"key":"ref_225","doi-asserted-by":"crossref","unstructured":"Wang, Z. (2016). Transactivation of Epidermal Growth Factor Receptor by G Protein-Coupled Receptors: Recent Progress, Challenges and Future Research. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17010095"},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/1476-4598-13-198","article-title":"The chemokine receptor CXCR7 interacts with EGFR to promote breast cancer cell proliferation","volume":"13","author":"Salazar","year":"2014","journal-title":"Mol. Cancer"},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jaci.2006.08.028","article-title":"Cysteinyl leukotrienes synergize with growth factors to induce proliferation of human bronchial fibroblasts","volume":"119","author":"Yoshisue","year":"2007","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_228","unstructured":"Riese, D.J. (2025, December 30). GPCR-EGFR Crosstalk. Available online: https:\/\/BioRender.com\/p5kjegr."},{"key":"ref_229","doi-asserted-by":"crossref","unstructured":"Kamato, D., Thach, L., Bernard, R., Chan, V., Zheng, W., Kaur, H., Brimble, M., Osman, N., and Little, P.J. (2015). Structure, Function, Pharmacology, and Therapeutic Potential of the G Protein, G\u03b1\/q,11. Front. Cardiovasc. Med., 2.","DOI":"10.3389\/fcvm.2015.00014"},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1043-2760(99)00232-5","article-title":"Activation of MAPK cascades by G-protein-coupled receptors: The case of gonadotropin-releasing hormone receptor","volume":"11","author":"Naor","year":"2000","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_231","doi-asserted-by":"crossref","unstructured":"Nell, R.J., Menger, N.V., Versluis, M., Luyten, G.P.M., Verdijk, R.M., Madigan, M.C., Jager, M.J., and van der Velden, P.A. (2021). Involvement of mutant and wild-type CYSLTR2 in the development and progression of uveal nevi and melanoma. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-07865-x"},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"100163","DOI":"10.1074\/jbc.RA120.015352","article-title":"Direct evidence that the GPCR CysLTR2 mutant causative of uveal melanoma is constitutively active with highly biased signaling","volume":"296","author":"Ceraudo","year":"2021","journal-title":"J. Biol. Chem."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1055\/a-1513-0789","article-title":"The Genetics of Uveal Melanoma: Overview and Clinical Relevance","volume":"238","author":"Riechardt","year":"2021","journal-title":"Klin. Monbl. Augenheilkd."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/ng.3549","article-title":"Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma","volume":"48","author":"Moore","year":"2016","journal-title":"Nat. Genet."},{"key":"ref_235","doi-asserted-by":"crossref","unstructured":"Bol, K.F., Donia, M., Heegaard, S., Kiilgaard, J.F., and Svane, I.M. (2020). Genetic Biomarkers in Melanoma of the Ocular Region: What the Medical Oncologist Should Know. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21155231"},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"4624","DOI":"10.18632\/oncotarget.6614","article-title":"Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4","volume":"7","author":"Johansson","year":"2016","journal-title":"Oncotarget"},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/s41388-020-01569-5","article-title":"Functional characterization of uveal melanoma oncogenes","volume":"40","author":"Ma","year":"2021","journal-title":"Oncogene"},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"eabj4243","DOI":"10.1126\/scisignal.abj4243","article-title":"Uveal melanoma-associated mutations in PLC\u03b24 are constitutively activating and promote melanocyte proliferation and tumorigenesis","volume":"14","author":"Phan","year":"2021","journal-title":"Sci. Signal."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1158\/1535-7163.MCT-12-1020","article-title":"Inhibition of mutant GNAQ signaling in uveal melanoma induces AMPK-dependent autophagic cell death","volume":"12","author":"Ambrosini","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ccell.2017.04.002","article-title":"RasGRP3 Mediates MAPK Pathway Activation in GNAQ Mutant Uveal Melanoma","volume":"31","author":"Chen","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"9511","DOI":"10.1200\/JCO.2016.34.15_suppl.9511","article-title":"A randomized phase 2 study of trametinib with or without GSK2141795 in patients with advanced uveal melanoma","volume":"34","author":"Shoushtari","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_242","unstructured":"(2025, December 26). Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma, Available online: https:\/\/clinicaltrials.gov\/study\/NCT01979523?tab=results."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1158\/1078-0432.CCR-20-2860","article-title":"Combined Inhibition of G\u03b1q and MEK Enhances Therapeutic Efficacy in Uveal Melanoma","volume":"27","author":"Hitchman","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1158\/1535-7163.MCT-19-0098","article-title":"Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071","volume":"19","author":"Larkin","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1038\/s41416-022-02133-6","article-title":"A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma","volume":"128","author":"Carlino","year":"2023","journal-title":"Br. J. Cancer"},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"4724","DOI":"10.1038\/onc.2013.418","article-title":"Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations","volume":"33","author":"Chen","year":"2014","journal-title":"Oncogene"},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"16779","DOI":"10.1007\/s00210-025-04297-3","article-title":"PI3 K\/AKT\/mTOR pathway and its role in breast cancer stem cells","volume":"398","author":"Prabhu","year":"2025","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40364-023-00471-y","article-title":"Elevated ZNF704 expression is associated with poor prognosis of uveal melanoma and promotes cancer cell growth by regulating AKT\/mTOR signaling","volume":"11","author":"Luo","year":"2023","journal-title":"Biomark. Res."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1167\/iovs.09-3974","article-title":"The PI3K\/Akt and mTOR\/P70S6K signaling pathways in human uveal melanoma cells: Interaction with B-Raf\/ERK","volume":"51","author":"Babchia","year":"2010","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"100800","DOI":"10.1016\/j.preteyeres.2019.100800","article-title":"Uveal melanoma: Towards a molecular understanding","volume":"75","author":"Smit","year":"2020","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_251","doi-asserted-by":"crossref","unstructured":"Zhang, L., Zhang, F., Liang, H., Qin, X., Mo, Y., Chen, S., Xie, J., Hou, X., Deng, J., and Hao, E. (2025). Hippo\/YAP signaling pathway in colorectal cancer: Regulatory mechanisms and potential drug exploration. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1545952"},{"key":"ref_252","doi-asserted-by":"crossref","unstructured":"Zhang, J., Wu, H., Ren, X., Chen, Z., Ye, S., Chen, S., Fang, J., Wu, Q., and Zhao, T. (2025). Hippo\/YAP signaling\u2019s multifaceted crosstalk in cancer. Front. Cell Dev. Biol., 13.","DOI":"10.3389\/fcell.2025.1595362"},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.ccr.2014.04.017","article-title":"Mutant Gq\/11 promote uveal melanoma tumorigenesis by activating YAP","volume":"25","author":"Yu","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ccell.2019.01.009","article-title":"A Platform of Synthetic Lethal Gene Interaction Networks Reveals that the GNAQ Uveal Melanoma Oncogene Controls the Hippo Pathway through FAK","volume":"35","author":"Feng","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1016\/j.celrep.2019.03.021","article-title":"YAP\/TAZ Activation Drives Uveal Melanoma Initiation and Progression","volume":"29","author":"Li","year":"2019","journal-title":"Cell Rep."},{"key":"ref_256","doi-asserted-by":"crossref","unstructured":"Djidjik, R., Lamara Mahammed, L., Berkani, L.M., Allam, I., Benmoussa, A.H., Gharnaout, M., and Belaid, B. (2025). JAK\/STAT in human diseases: A common axis in immunodeficiencies and hematological disorders. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1669688"},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11010-024-04983-5","article-title":"Mechanisms and therapeutic prospect of the JAK-STAT signaling pathway in liver cancer","volume":"480","author":"Jia","year":"2025","journal-title":"Mol. Cell Biochem."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"523","DOI":"10.2147\/ITT.S485670","article-title":"JAK-STAT Signaling in Autoimmunity and Cancer","volume":"14","author":"Parveen","year":"2025","journal-title":"Immunotarg. Ther."},{"key":"ref_259","first-page":"30030","article-title":"STAT signaling pathways in immune cells and their associated mechanisms in cancer pathogenesis","volume":"15","author":"Sohrabi","year":"2025","journal-title":"Bioimpacts"},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1016\/j.jid.2021.11.035","article-title":"Expression Differences in BCL2 Family Members between Uveal and Cutaneous Melanomas Account for Varying Sensitivity to BH3 Mimetics","volume":"142","author":"Mukherjee","year":"2022","journal-title":"J. Investig. Dermatol."},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"110712","DOI":"10.1016\/j.jbc.2025.110712","article-title":"Inhibition of anti-apoptotic BCL2 overcomes adaptive resistance to co-targeting of the protein kinase FAK and MEK in GNAQ-driven uveal melanoma","volume":"301","author":"Lubrano","year":"2025","journal-title":"J. Biol. Chem."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1159\/000514650","article-title":"Is Uveal Melanoma a Hormonally Sensitive Cancer? A Review of the Impact of Sex Hormones and Pregnancy on Uveal Melanoma","volume":"7","author":"Miller","year":"2021","journal-title":"Ocul. Oncol. Pathol."},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1159\/000512174","article-title":"Estrogen Receptor Is Expressed in Uveal Melanoma: A Potential Target for Therapy","volume":"7","author":"Schoenfield","year":"2021","journal-title":"Ocul. Oncol. Pathol."},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"27603","DOI":"10.18632\/oncotarget.15178","article-title":"The association between nuclear receptors and ocular diseases","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"key":"ref_265","doi-asserted-by":"crossref","unstructured":"Lucas, L.M., Cullum, R.L., Dwivedi, V., Markham, J.A., Woggerman, J.N., Kelley, C.M., Knerr, E.L., Cook, L.J., Lucas, H.C., and Waits, D.S. (2023). ERBB4 drives the proliferation of BRAF WT melanoma cell lines. medRxiv.","DOI":"10.1101\/2022.06.20.22276663"},{"key":"ref_266","unstructured":"Lucas, L.M., Cullum, R.L., Markham, J.A., Woggerman, J.N., Dwivedi, V., Mohamedelhassan, R.H., Cook, L.J., Kelley, C.M., Knerr, E.L., and Kaufmann, D.P. (2023). ERBB4 mutant alleles may drive BRAF WT melanomas. medRxiv."},{"key":"ref_267","unstructured":"Dwivedi, V., Lucas, L.M., Cooke, R., Davis, J., Wilson, E., Scott, M., O\u2019Daniel, K., Dion, C., Kerley, J., and Zelan, M. (2024). Human melanoma cell lines that possess wild-type BRAF alleles but are dependent on ERBB4 and ERBB2. bioRxiv."},{"key":"ref_268","doi-asserted-by":"crossref","unstructured":"Wilson, E., Conway, A., and Riese, D.J. (2026). Cancer Cell Line Encyclopedia Data Suggest that Ligands for ERBB Family Receptors May Drive BRAF-WT Melanomas. bioRxiv.","DOI":"10.64898\/2026.03.16.712185"},{"key":"ref_269","unstructured":"(2026, March 29). MM28\u2014CRL-3295. Available online: https:\/\/www.atcc.org\/products\/crl-3295."},{"key":"ref_270","unstructured":"(2026, March 29). MP41\u2014CRL-3297. Available online: https:\/\/www.atcc.org\/products\/crl-3297."},{"key":"ref_271","unstructured":"(2025, June 16). MP46\u2014CRL-3298. Available online: https:\/\/www.atcc.org\/products\/crl-3298."},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"6991","DOI":"10.1167\/iovs.12-10427","article-title":"High throughput mass spectrometry-based mutation profiling of primary uveal melanoma","volume":"53","author":"Daniels","year":"2012","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_273","first-page":"1067","article-title":"Role of epidermal growth factor receptor in the metastasis of intraocular melanomas","volume":"39","author":"Ma","year":"1998","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_274","first-page":"2023","article-title":"Expression of epidermal growth factor receptor: Risk factor in uveal melanoma","volume":"41","author":"Hurks","year":"2000","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1001\/archopht.119.3.373","article-title":"Overexpression of epidermal growth factor receptor restricted to macrophages in uveal melanoma","volume":"119","author":"Scholes","year":"2001","journal-title":"Arch. Ophthalmol."},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1080\/02713680601161220","article-title":"Expression of epidermal growth factor receptor, ezrin, hepatocyte growth factor, and c-Met in uveal melanoma: An immunohistochemical study","volume":"32","author":"Mallikarjuna","year":"2007","journal-title":"Curr. Eye Res."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/CMR.0b013e3283471073","article-title":"A phase II study of gefitinib in patients with metastatic melanoma","volume":"21","author":"Patel","year":"2011","journal-title":"Melanoma Res."},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.18240\/ijo.2022.10.02","article-title":"Pharmacological drug screening to inhibit uveal melanoma metastatic cells either via EGF-R, MAPK, mTOR or PI3K","volume":"15","author":"Kassumeh","year":"2022","journal-title":"Int. J. Ophthalmol."},{"key":"ref_279","unstructured":"(2026, July 18). NCT03775525: Study Evaluating GZ17-6.02 in Patients with Advanced Solid Tumors or in Combination with Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer (GEN602), Available online: https:\/\/clinicaltrials.gov\/study\/NCT03775525."},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"328","DOI":"10.18632\/oncotarget.28586","article-title":"GZ17-6.02 kills PDX isolates of uveal melanoma","volume":"15","author":"Booth","year":"2024","journal-title":"Oncotarget"}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/16\/8\/1079\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T15:24:40Z","timestamp":1784820280000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/16\/8\/1079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":280,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["biom16081079"],"URL":"https:\/\/doi.org\/10.3390\/biom16081079","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]}}}